Jan 2009

INTRODUCTION TO
JUBILANT
FULLY INTEGRATED SOLUTIONS
IN GENERICS
Jan 2009
Jubilant fact sheet
Incorporated in 1978 and headquartered in New Delhi - India
Ownership of the company 52% with founders, 30% with PE and
institutions and 18% with public
Over 25 years of experience in Chemical & Knowledge-based industry
Strong Financials: Net sales of 416 million $ in FY 2007, PAT of $ 52
million
Employs 4,466 people including about 1,050 in R&D
Subsidiaries in Europe (Jubilant Europe), USA & China
Global positions in key products, exported to over 120 countries
Jan 2009
Jubilant Pharmaceuticals fact sheet
Incorporated in 1993
Based in Gent Belgium
Subsidiary of Jubilant Life Sciences since 2004
Broad-spectrum services and products provider to pharmaceutical
marketing companies in Europe
Knowledge-based company with excellent track record in national
MAs, MRPs and DCP procedures
Jan 2009
Moving up the Pharmaceutical Value Chain
1980-85 1985-90 1990-95 1995-2000 2000-2003 2004
Generic
Products
Organic
Intermediates
Performance
Chemicals
CRAMS
APIs
Discovery
Services
Regulatory
Services
Jan 2009
Core business
Jubilant Pharmaceuticals is a totally backward integrated service and
product provider for generic pharmaceutical companies.

Our core business and competences are:

Out-licensing with supply of fully in-house developed generics.
Manufacturing site transfers with production at the in-house facility.
Regulatory Services
Clinical research at the in-house facility in Delhi, India.
Jan 2009
Backward integration
OUT-
LICENSING
SUPPLY
RA
Perfect synergism from API development up to supply of the
finished dosage form, guaranteeing reliability in quality and
timing.
Jan 2009
Benefits of backward integration
OUT-
LICENSING
strong R&D and manufacturing
capacities at Jubilant India

Jubilant Pharmaceuticals as the
single contact point in Europe for
licensing, registration and supply

Qualitative supply of dosage form
products

Competitive pricing throughout the
entire supply term
Jan 2009
API : In-house API formulation & production

R&D Formulation :
Plain dosage forms
Added-value
Controlled and sustained release

BE studies : In-house Clinical center

In-house Regulatory Affairs expertise

In-house production of pharmaceutical
dosage forms

In-house GDP logistics with GMP certification :
EU release
Jubilants facilities
Jan 2009
Jubilant Life Sciences API





Jubilant develops a range of
APIs and intermediates in therapeutic
categories of the central nervous
system, cardiovascular system, gastro-
intestinal and anti-infectives.

These APIs are the core of
the finished dosage form developments.

Commercially available molecules with DMF/
CoS include:
Carbamazepine, Oxcarbazepine, Citalopram,
Lamotrigine, Risperidone, Tramadol,
Esomeprazole, Losartan, Pantoprazole,
Olanzapine...


Jan 2009
Jubilant Clinsys Clinical Research
Wholly owned subsidiaries based in Delhi, India and Philadelphia, US
Bioavailability, bioequivalence, pharmacokinetic and phase 1 clinical
studies
46 bed facility spread in ~35,000 sq. ft. area in Delhi certified by
DCGI-India, Bfarm (DE) and MEB (NL)
Own Bio-analytical, PK, Clinical Lab, Statistical and quality assurance
under one roof
Clinical research started in June 2005
Jan 2009
R&D Formulation Center
The development work on dosage
forms has a therapeutic focus on
Central Nervous System
Cardiovascular System
Anti-infective
Respiratory System
Anti-diabetic treatment
A dedicated team of more than
100 scientists is working in
laboratories equipped with the
latest scientific instruments.

Jan 2009
Dosage form manufacturing
Jubilant owns a finished dosage forms c-GMP compliant
manufacturing facility at Roorkee, India.

The facility was set up in July 2007 and EU-GMP approved by the
UK-MHRA in record time.

Current annual production capacity is 1.2 billion tablets and 330
million capsules with expansion foreseen in the near future.

Production capabilities span
across various IR, NDDS and taste
masked oral solids through:
wet and dry granulation
direct compression
encapsulation
spheronisation
extrusion
Jan 2009
Jubilants strengths
Complete project management in-house
Availability of large number of qualified experts
Strict adherence to EU/US FDA guidelines
High quality Drug Master Files and CoS
Highly qualified and experienced scientists
Novel, patented and non-infringing
technologies
Providing integrated offers for licensing and
supply of finished dosage forms to clients in
Europe
Skill / Technologies
Quality & Reliability
One stop solution
Cost
Significant cost saving through full integration
Jan 2009
Main Focus
Jubilant understands the outsourcing requirements of its customers
and transforms their needs into solutions.

Long-term supply of finished dosage forms following either :

OUT-LICENSING

OR

TURNKEY
MANUFACTURING
SITE TRANSFERS
Jan 2009
One stop solution
Our customers are companies which :

market & sell medicinal products

are eager to expand their product portfolio/geographic
territory and want to be first to the market

wish to upgrade to state-of-the-art active substances and
finished dosage form manufacturing

prefer to concentrate their resources on marketing and
choose Jubilant as one stop solution for research,
development, RA and supply.